Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 6/20 | 0.62 |
| ▸ | GLRA2 | P23416 | 6/20 | 0.62 |
| ▸ | PTAFR | P25105 | 4/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | GUSB | P08236 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14047657 | 0.80 | GLRA1 (0.63) | GLRA1GLRA2PTAFRCYP2C9HSD17B10 | |
| Ginkolide B SCHEMBL16407904 | 0.76 | PTAFR (1.00) | GLRA1GLRA2PTAFRCYP2C9HSD17B10 | |
| Ginkolide B SCHEMBL14279903 | 0.76 | PTAFR (1.00) | GLRA1GLRA2PTAFRCYP2C9HSD17B10 | |
| Ginkolide B SCHEMBL464784 | 0.76 | PTAFR (1.00) | GLRA1GLRA2PTAFRCYP2C9HSD17B10 | |
| Ginkolide B SCHEMBL29495629 | 0.76 | PTAFR (1.00) | GLRA1GLRA2PTAFRCYP2C9HSD17B10 | |
| Ginkolide B SCHEMBL12714280 | 0.76 | PTAFR (1.00) | GLRA1GLRA2PTAFRCYP2C9HSD17B10 | |
| Ginkolide B SCHEMBL464783 | 0.76 | PTAFR (1.00) | GLRA1GLRA2PTAFRCYP2C9HSD17B10 | |
| Ginkolide B SCHEMBL29410795 | 0.76 | PTAFR (1.00) | GLRA1GLRA2PTAFRCYP2C9HSD17B10 | |
| Ginkolide B SCHEMBL13702797 | 0.76 | PTAFR (1.00) | GLRA1GLRA2PTAFRCYP2C9HSD17B10 | |
| Ginkolide B SCHEMBL14029435 | 0.76 | PTAFR (1.00) | GLRA1GLRA2PTAFRCYP2C9HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296210-A1 | PHARMACOLOGICAL TREATMENT OF COGNITIVE IMPAIRMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-02 | — | — | US | disclosed |
| US-8729067-B2 | Pharmacological treatment of cognitive impairment | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-05-20 | — | — | US | disclosed |
| US-20080009475-A1 | PHARMACOLOGICAL TREATMENT OF COGNITIVE IMPAIRMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009475-A1 | PHARMACOLOGICAL TREATMENT OF COGNITIVE IMPAIRMENT | GABRE, GABRB2, SLC6A1 | GLRA1 126/4885GLRA2 92/4885PTAFR 2133/4885 |
| US-20140296210-A1 | PHARMACOLOGICAL TREATMENT OF COGNITIVE IMPAIRMENT | GABRE, GABRB2, SLC6A1 | GLRA1 126/4885GLRA2 92/4885PTAFR 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.